The German chemical conglomerate claims the closure is unavoidable due to much needed rationalisation. It will happen by the end of February.
Malcolm Parry, Group HR manager for Knoll, the division of BASF Pharma which owns the r&d plant, said, "Our employees will receive more than the statutory redundancy payment." He refused to comment further.
The closure is part of a business plan drawn up by BASF Pharma in April 2000.
Ian Hunneyball, the company’s director of r&d in the UK, said, "It’s an immense disappointment that we were unable to secure more jobs for our employees here in Nottingham. We will do everything we can to support all redundant staff and assist them to make decisions about their future."
By Karen Higginbottom